Results 91 to 100 of about 5,464 (192)

Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention [PDF]

, 2001
CONTEXT: Abciximab, a potent inhibitor of the platelet glycoprotein IIb/IIIa receptor, reduces thrombotic complications in patients undergoing percutaneous coronary intervention (PCI).
Tcheng, J.E. (James), Akkerhuis, K.M. (Martijn), Topol, E.J. (Eric), Deckers, J.W. (Jaap), Balog, C., Anderson, K. (Keaven), Lincoff, A.M. (Michael), Califf, R.M. (Robert), Simoons, M.L. (Maarten), Boersma, H. (Eric)   +9 more
core  

Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy

, 2000
OBJECTIVESThis study determined the incidence of pseudothrombocytopenia during abciximab therapy administered for percutaneous coronary interventions and compared the clinical course of patients with pseudothrombocytopenia with the clinical courses of ...
Simoons, Maarten L, Simoons, Maarten, Cabot, Catherine F, Maarten L Simoons, Topol, EJ, Damaraju, Lakshmi V, Catherine F Cabot, Topol, Eric J, Sane, DC, Lakshmi V Damaraju, Sane, David C, David C Sane, Mascelli, Mary Ann, Eric J Topol, Robert M Califf, Harrington, Robert A, Harrington, RA, Mary Ann Mascelli, Califf, Robert M, Mascelli, MA, Robert A Harrington, Damaraju, LV, Cabot, CF, Califf, RM   +23 more
core   +1 more source

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

, 2012
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates it may also promote dissolution of platelet-rich thrombi.
Marciniak, Stanley J. Jr., Frelinger, Andrew L. III, Jordan, Robert E., Marchese, Peter J., Furman, Mark I., Jakubowski, Joseph A., Mascelli, Mary A., Michelson, Alan D.   +7 more
core  

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both?

Vascular Health and Risk Management, 2006
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Worcester, MA, USA; 2Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 3UMass Memorial ...
Matthew A Silva, Jennifer L Donovan, Pritesh J Gandhi, Gregory A Volturo   +3 more
doaj  

Allergic reaction to abciximab with atypical manifestations

, 2011
Abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana) is an intravenous agent that had been approved for treatment of acute coronary syndrome undergoing coronary interventions.
Al-Moghairi, Abdulrahman M., Abdullah, Moheeb A., Abdulrahman M. Al-Moghairi, Moheeb A. Abdullah   +3 more
core   +1 more source

Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

, 2015
Background: Although intracoronary abciximab failed to improve prognosis compared with intravenous route in unselected ST-segment elevation myocardial infarction (STEMI) patients, little is known about the role of intracoronary abciximab in diabetic ...
Eitel, Ingo, GALASSO, Gennaro, Abreu Gonzalez, Pedro, de Smet, Bart J. G. L., Mahmoud, Karim D., Iversen, Allan Zeeberg, PICCOLO, RAFFAELE, Dominguez Rodriguez, Alberto, PISCIONE, Federico, Dominguez-Rodriguez, Alberto, Thiele, Holger, Abreu-Gonzalez, Pedro, Gu, Youlan L.   +12 more
core   +1 more source

Time and Dose Dependent Augmentation of Inhibitory Effects of Abciximab by Aspirin

, 2001
SummaryAspirin and abciximab independently decrease the incidence of cardiac events. To identify potential interactions, antiplatelet effects of abciximab were characterized in blood from healthy subjects given aspirin. Platelet activation was determined
David Schneider, Douglas Taatjes, Burton Sobel, Michael Holmes, Patricia Baumann   +4 more
core   +1 more source

Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

, 2007
This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by search-ing CCIS, and the ...
신상진, 김진현, 이영희, 김은주   +3 more
core  

Los inhibidores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos. The IIb/IIIa platelet receptor inhibitors in the acute coronary syndromes.

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2001
Los inhibidores de los receptores IIb/IIIa, un nuevo grupo de antiagregantes plaquetarios, son potentes bloqueadores del receptor que media la agregación plaquetaria y de ese modo bloquean la vía final común de la formación del trombo plaquetario.
Fidel Manuel Cáceres Lóriga, Horacio Pérez López   +1 more
doaj  

Antiagregantes plaquetarios: mecanismos de acción y riesgos asociados al uso Platelet antiaggregants: mechanisms of action and use asocied risks

Vitae, 2009
Las Enfermedades Cardiovasculares son la principal causa de muerte en el mundo. Junto con los esfuerzos en disminuir los factores de riesgo cardiovascular, se recurre a diversos medicamentos para disminuir la morbimortalidad asociada a estas enfermedades,
Iván F PALOMO G, Constanza I TORRES U, Rodrigo E MOORE-CARRASCO, Marcelo A ALARCÓN L, Patricio J MARAGAÑO L   +4 more
doaj